A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK233705 In Healthy Volunteers.

A Single-centre, Randomized, Double-blind Placebo-controlled, Dose-ascending, Cross-over Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of GSK233705, Formulated With the Excipient Magnesium Stearate, in Healthy Volunteers

This study will investigate the safety and tolerability of inhaled doses of GSK233705 with a new formulation.

A single-centre, randomized, double-blind placebo-controlled, dose-ascending, cross-over study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK233705 (50, 100 and 200µg), formulated with the excipient magnesium stearate, in healthy volunteers.

Inclusion Criteria:

• Healthy male subjects 18-55 years old
• Non-Smokers

Exclusion Criteria:

• Any subject with breathing problems.
• High blood pressure and heart abnormalities.
• Any subjects currently taking prescription and non-prescription medications.